ArticleACS infectious diseases2015
Pathophysiology of Ebola Virus Infection: Current Challenges and Future Hopes.
Article in ACS infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Lassa fever: A comprehensive review of virology, clinical management, and global health implications.World journal of virology · 2025Review
- Nanovesicles as Potential Carriers for Delivery of Antiviral Drugs: A Comprehensive Review.Current drug delivery · 2025Review
- Novel antiviral approaches for Marburg: a promising therapeutics in the pipeline.Frontiers in microbiology · 2024Review
- Identifying the Anti-MERS-CoV and Anti-HcoV-229E Potential Drugs from theMolecules (Basel, Switzerland) · 2023Article
- Antiviral role of nanomaterials: a material scientist's perspective.RSC advances · 2022Review
- Antiviral potential of nanoparticles for the treatment of Coronavirus infections.Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) · 2022Review
- Development of nanoparticle-delivery systems for antiviral agents: A review.Journal of controlled release : official journal of the Controlled Release Society · 2021Review
- An overview of functional nanoparticles as novel emerging antiviral therapeutic agents.Materials science & engineering. C, Materials for biological applications · 2020Review
- The impact ofBMJ open · 2019Article
- Human transbodies that interfere with the functions of Ebola virus VP35 protein in genome replication and transcription and innate immune antagonism.Emerging microbes & infections · 2018Article
- Towards detection and diagnosis of Ebola virus disease at point-of-care.Biosensors & bioelectronics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The filoviruses, Ebola virus (EBOV) and Marburg virus (MARV), are among the deadliest viruses that cause disease in humans, with reported case fatality rates of up to 90% in some outbreaks. The high virulence of EBOV and MARV is largely attributed to the ability of these viruses to interfere with the host immune response. Currently, there are no approved vaccines or postexposure therapeutics, and treatment options for patients infected with EBOV are limited to supportive care. In this review, we discuss mechanisms of EBOV pathogenesis and its ability to subvert host immunity as well as several vaccines and therapeutics with respect to their evaluation in small animal models, nonhuman primates, and human clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.